|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.620 USD | +1.16% |
|
+1.55% | +0.77% |
| 12-24 | Sector Update: Health Care Stocks Rise Wednesday Afternoon | MT |
| 12-24 | Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise | MT |
| Capitalization | 113M 96.06M 89.04M 83.2M 155M 10.38B 164M 1.02B 404M 4.9B 424M 415M 17.82B | P/E ratio 2025 * |
-1.24x | P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 113M 96.06M 89.04M 83.2M 155M 10.38B 164M 1.02B 404M 4.9B 424M 415M 17.82B | EV / Sales 2025 * |
14.8x | EV / Sales 2026 * | 11.3x |
| Free-Float |
99.02% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
More news
| 1 day | +1.16% | ||
| 1 week | +1.55% | ||
| Current month | +0.77% | ||
| 1 month | +20.74% | ||
| 3 months | +35.75% | ||
| 6 months | +71.24% | ||
| Current year | +0.77% |
| 1 week | 2.5 |  | 2.63 |
| 1 month | 2.5 | | 2.66 |
| Current year | 2.5 | | 2.63 |
| 1 year | 0.89 | | 2.66 |
| 3 years | 0.89 | | 13.85 |
| 5 years | 0.89 | | 40 |
| 10 years | 0.89 | | 46.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
Steve Forte
CEO | Chief Executive Officer | 47 | 10/04/2025 |
Joseph O'Connell
CTO | Chief Tech/Sci/R&D Officer | 71 | 31/12/2020 |
Sandra Alves
AUD | Comptroller/Controller/Auditor | 47 | 29/02/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 62 | 28/02/2019 |
Steve Forte
BRD | Director/Board Member | 47 | 10/04/2025 |
Samarth Kulkarni
BRD | Director/Board Member | 47 | 31/10/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +14.29% | 1.33% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.16% | +1.55% | +114.75% | -78.80% | 112M | |
| +0.04% | -0.68% | -4.77% | +12.20% | 49.33B | |
| -1.56% | -1.00% | +14.23% | +2.87% | 40.71B | |
| +0.15% | +0.33% | +52.68% | +26.14% | 37.49B | |
| +1.92% | +1.44% | +23.10% | +42.46% | 31.07B | |
| -0.99% | -2.20% | +185.93% | +328.06% | 22.97B | |
| -3.01% | -3.74% | +69.03% | +145.51% | 17.08B | |
| Average | -0.33% | -0.41% | +64.99% | +68.35% | 28.39B | |
| Weighted average by Cap. | -0.35% | -0.52% | +42.76% | +65.55% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 7.65M 6.51M 6.03M 5.64M 10.51M 703M 11.14M 68.92M 27.36M 332M 28.69M 28.1M 1.21B | 10M 8.5M 7.88M 7.37M 13.73M 919M 14.56M 90.09M 35.77M 434M 37.5M 36.73M 1.58B |
| Net income | -90.21M -76.72M -71.12M -66.46M -124M -8.29B -131M -813M -323M -3.91B -338M -331M -14.23B | - |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
129
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 2.620 $ | +1.16% | 290,050 |
| 22/01/26 | 2.590 $ | 0.00% | 1,001,237 |
| 21/01/26 | 2.590 $ | +0.39% | 937,440 |
| 20/01/26 | 2.580 $ | 0.00% | 4,157,648 |
| 16/01/26 | 2.580 $ | +0.39% | 533,376 |
Delayed Quote Nasdaq, January 23, 2026 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.620USD
Average target price
3.000USD
Spread / Average Target
+14.50%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RPTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition